parkirick
Forum Replies Created
-
https://parkinsonsnewstoday.com/news/buntanet-shown-halt-cognitive-decline-early-parkinsons-trial/
parkinsonsnewstoday.com
Buntanetap shown to halt cognitive decline in early Parkinson's trial
In a trial, once-daily buntanetap halted cognitive decline in early-stage Parkinson's and improved cognition in patients with mild dementia.
-
More on the progress of buntanetapa;
https://www.neurologylive.com/view/buntanetap-transitioning-crystal-form-following-fda-go-ahead
neurologylive.com
Buntanetap Transitioning to Crystal Form Following FDA Go-Ahead
The investigational therapy, which targets neurodegeneration, has shown promise in phase 2 and 3 studies of Alzheimer disease and Parkinson disease, with additional studies on the way.
-
I too have been following the progress with buntanetap as it wends its way through the trial process. At first, the Phase III results were hung up in a data review process but those issues were resolved (see text). The latest news is very encouraging. Here is an excerpt from the article:
“Newly announced data from a phase 3 study (NCT05357989) of patients with
Parkinson disease (PD) showed that treatment with investigational
buntanetap was safe and well tolerated, with noted improvements in motor
and nonmotor activities, as well as cognitive function. Buntanetap,
formerly known as Posiphen or ANVS401, targets neurodegeneration by
inhibiting amyloid-ß, tau, alpha-synuclein, and TDP-43.<sup>1″</sup>
neurologylive.com
Buntanetap Improves Motor, Nonmotor and Cognitive Symptoms of Parkinson Disease in Phase 3 Study
Over the 3-year treatment period, buntanetap resulted in improvements in motor and nonmotor functions in patients with postural instability and gait difficulty, a group with faster disease progression.